EGFR and head and neck squamous cell carcinoma: The finding that EGFR blockade enhanced the effects of radiation therapy in HNSCC in preclinical studies contributed to the landmark randomized phase 3 clinical trial reporting enhanced survival and locoregional control when cetuximab was administered with radiation [8,9,10].